BALTIMORE, MD, March 19, 2024 –, CoapTech, Inc., a medical device company delivering transformative solutions for minimally-invasive surgery, announced today the market launch and historic first bedside use case of its second generation magnetic balloon catheter. The magnetic balloon catheter is a key component of the PUMA-G System™ which enables ultrasound placement of gastrostomy tubes (i.e. permanent feeding tubes), necessary to nourish patients to recovery. The PUMA-G System is manufactured in Baltimore in collaboration with The LaunchPort™.

This first bedside use case was completed in the critical care unit (better known as ICU) at the University of Maryland Baltimore Washington Medical Center (UM BWMC) and was performed by Darwin Ashbaker, MD, and Stephen Griffin, PA, on February 27, 2024.

John Sackett and Rich 250 x 600 px

Discover the Future of Healthcare with John Sackett, Executive Vice President & COO of Adventist Healthcare, on BioTalk with Rich Bendis.

In this episode, John Sackett shares his insights into the changing landscape of healthcare delivery. From his early days as an administrative assistant to his current role, John's journey offers invaluable lessons on leadership and innovation in the healthcare industry.

Join us as we explore Adventist Healthcare's role in the BioHealth Capital Region (BHCR) and explore the transformative changes in healthcare delivery. Gain valuable insights into the challenges and innovations reshaping healthcare post-COVID and learn how Adventist Healthcare is leading the way in patient-centered care.

Listen now via your favorite podcast platform:

Apple -
Google -
Spotify -
Amazon Music -
TuneIn -

In a candid and inspiring segment, John opens up about his personal journey of managing cystic fibrosis while excelling in his career. Discover the remarkable advancements in the treatment and life expectancy of CF patients, highlighting the power of innovation and resilience in overcoming adversity.

Don't miss this enlightening episode as we navigate the evolving landscape of BioHealth Innovation and the BHCR Region with John Sackett, a visionary leader shaping the future of healthcare.


Navigating the uncertain road of entrepreneurship

This year marks the year of the dragon in Chinese culture. The dragon symbolises nobility, good fortune, and vitality and presents a year of auspicious opportunities. Against the backdrop of 2023, I’d say this is a fortune well worth getting behind.

The past year has been difficult for most companies, but for business leaders it has meant summoning inner strength and resilience. If you’re an entrepreneur, give yourself a pat on the back. You’ve taken an ambitious and courageous leap to launch and build a company during what has been a challenging economic climate for life sciences and biotech startups. The post-pandemic financial downturn saddled us with the impacts of inflation, volatile supply chains, and a stagnant venture funding environment. Research and developing innovation are a risky business even in the best financial conditions, so give yourself credit for tackling this important work during a time of uncertainty.


Amsterdam, March 15, 2024 – The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into 'microbiomes' and economically interesting applications thereof. The funds, which will add to €150 million that the dozens of consortium members and partners themselves contribute, will support the activities of a national 'Holomicrobiome Institute' over the next ten years.

In the consortium, ten Dutch universities, five university-medical centers, four universities of applied sciences, and many other knowledge organizations work together with dozens of small and large companies (including MIMETAS) and societal organizations.


Dozens of life sciences startups and early-stage company companies are honing their pitch decks and looking to head to New York, the center of the financial world, for a one-day investor and partnering event in hopes of securing financial partnerships.

In May, Johnson & Johnson – JLABS will hold its third annual Investor & Partnering Day in New York City at the New York Genome Center, a non-profit hub for collaborative genomic research and the home of JLABS @ NYC. The partnering day offers participating companies multiple meetings with investor organizations to highlight their science & technology, expand their investor network, and potentially securing funding to support ongoing and future operations.

zephyr logo2

MCLEAN, Va.--(BUSINESS WIRE)--Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others. The company is developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease.


ROCKVILLE, Md.March 13, 2024 /PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant milestone in partnership with Eilean Therapeutics LLC: the start of Phase 1 trial of balamenib (ZE63-0302), a highly selective inhibitor of the menin–KMT2A binding interaction, under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutics Goods Administration (TGA).

"Balamenib has a highly differentiated pre-clinical profile which indicates important advantages over molecules in the same class in safety, tolerability and feasibility of outpatient treatment," commented Bill Farley, CBO at Expert Systems. "We are proud that our comprehensive hybrid AI-based platform has helped accelerate the development of a new promising & safe treatment for AML."


By Sara Gilgore – Staff Reporter, Washington Business Journal - Rockville’s RegenxBio Inc. (NASDAQ: RGNX) has raised $140 million in a public offering, four months after making significant cuts to extend its cash runway.

The clinical-stage biotech, which is developing gene therapies for retinal and neurodegenerative diseases, closed the previously announced offering Monday, a company spokesperson confirmed to the Washington Business Journal.


Life science company working to develop ultrasonic bone fracture healing technology

 COLUMBIA, Md. (March 11, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Seed Funds investment in Sonogen Medical, a medical device company based in Maryland.

“Roughly eight percent of the seven million bone breaks annually in the United States fail to heal on their own. At Sonogen Medical, we are combining decades of experience to create a device that supports faster more efficient healing processes for patients,” said Jason Winder, CEO of Sonogen Medical. “Thanks to TEDCO’s investment we can continue our research and development efforts, propelling us towards an efficient, cost-effective solution.”



OSLO/LONDON, March 11, 2024 - An international consortium of researchers specialising in human challenge studies is embarking on a US$57 million project to develop advanced, virus-blocking coronavirus vaccines that could stop SARS-CoV-2 and other coronaviruses from infecting people in the first place.

Led by Imperial College London and co-funded by the European Union’s Horizon Europe Programme and CEPI, the Coalition for Epidemic Preparedness Innovations, the consortium of more than a dozen scientific teams and organisations will begin by running trials to select particular viruses and identify the best conditions under which to safely induce infection in healthy volunteers. A human challenge study is a carefully managed medical research study, during which volunteers are intentionally given an infection in a safe way, with healthcare support.


Hear from ARPA-H Director Renee Wegrzyn, PhD and White House Initiative on Women’s Health Research Director Carolyn Mazure, PhD on the new $100M ARPA-H Sprint for Women’s Health Program and the White House plans, plus insights from WHAM Founder Carolee Lee and AMWA President Elizabeth Garner, MD. If you are an innovator, founder, funder, researcher or care about driving meaningful change in advancing the health of women, this event is for you!


There are more than 10,000 known rare diseases and only a few hundred have safe, effective treatments. ARPA-H’s latest project aims to change that and deliver hope and improved outcomes to millions of Americans.

Introducing MATRIX. Short for ML/AI-Aided Therapeutic Repurposing in eXtended uses, MATRIX intends to build a machine learning platform to rapidly pinpoint and validate existing medications to treat diseases that have no therapies.

• The platform will be open-sourced and include an interactive heatmap displaying predicted efficacy scores for approved drugs against other diseases.


Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”)

Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive agreement for a private placement financing of $50 million that will be used to advance two lead product candidates through Phase 2 clinical readouts in 2025


Program to ‘fast-track’ emerging companies reflects how innovation and entrepreneurship are growing as VCU sets funding records.

After years of supporting startups that license inventions created by university researchers, Virginia Commonwealth University’s Office of the Vice President for Research and Innovation has launched its first formal Startup Accelerator program.

“Our accelerator will fast-track our VCU-borne companies, giving them more personalized coaching and advisory services from our lineup of entrepreneur experts-in-residence,” said P. Srirama Rao, Ph.D., vice president for research and innovation. “Innovation is taking place at a rapid pace at VCU, and this program will further raise our national visibility and continue to position Central Virginia as a key American technological hub.”

cartesiantherapeutics logo

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases

GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced its plans to transition its corporate headquarters to Frederick, Maryland. The approximately 20,000 square foot state-of-the-art current good manufacturing practice (cGMP) compliant facility has clinical and commercial manufacturing scale capabilities designed to support the Company's maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases.


By Vic Suarez - The COVID-19 global pandemic has underscored the critical need for resilient and secure supply chains, particularly in the pharmaceutical industry. As the United States grapples with near-all-time high drug shortages1 and the vulnerability of its supply chain, it has become a national security imperative to address the overreliance on imports for active pharmaceutical ingredients (API) to the United States. Today, China is the sole source for about 20% of the API of our most vital medicines.2 More dangerously, China’s overwhelming global dominance of the key starting materials (KSM) required to produce these essential medicines cannot be readily substituted due to the current levels of market concentration: approximately 45% of KSM, a vital subcategory of API, are solely sourced from China, according to the API Innovation Center.3 To be sure, this level of import dependence on any single nation poses a serious risk to the nation’s general preparedness and resilience, and could become devastating in a crisis.


Maryland thought leaders support the diversification of Maryland’s workforce

COLUMBIA, Md. (March 5, 2024) – TEDCO, Maryland’s economic engine for technology companies, recently announced the newly appointed Equitech Growth Commission, that manages the Cultivate Maryland initiative.

The Cultivate Maryland initiative was established by the Maryland General Assembly as the Equitech Growth Fund and Commission during the 2023 legislative session to increase Maryland’s competitiveness as an innovation economy. This decision was made in response to a recent study that outlined the need for promoting more diversity and inclusion in Maryland’s technology ecosystem.

As established, the Cultivate Maryland initiative is managed by a 24-member commission – the Equitech Growth Commission. Of these individuals, 10 are appointed by the Governor, three are appointed by the Speaker of the House, three are appointed by the President of the Senate.

“Maryland needs more strategies to support the growth and development of our economy,” said Governor Wes Moore. “The Equitech Growth Commission is one of the many new strategies in place to bring Maryland to the forefront of the competition, and we are excited to see the positive change they bring.”


Rockville Economic Development, Inc. (REDI) is set to launch its first BioBoost series on March 20, 2024, in Rockville, MD. This pioneering event, titled "The Future of Bio/Life Science Funding in 2024," promises to be a cornerstone for professionals in the bio/life science sector. Attendees will have the unique opportunity to delve into the latest investment trends, overcome industry challenges, and discover new funding opportunities through insightful discussions led by esteemed industry experts.

BioBuzz Article Images 46

In honor of Women’s History Month, which kicks off today, we wanted to highlight 10 incredible women making a mark in the life sciences in the BioHealth Capital Region. This is just the tip of the iceberg.

Arti Santhanam, Executive Director, Emerging Technology Centers (ETC)
Dr. Arti Santhanam was recently appointed Executive Director of Emerging Technology Centers (ETC). While new to the role, Dr. Santhanam is a long-time player in the BioHealth Capital Region.

Dr. Santhanam’s contributions over the last decade at TEDCO, especially within her role in the Maryland Innovation Initiative (MII), have been instrumental in fostering Maryland’s diverse and innovative ecosystem. Established in 2012, MII has invested $52.3M, resulting in 176 startups from notable universities like Johns Hopkins, the University of Maryland, and Morgan.


Maryland company continues toward goal of supporting improved patient safety

COLUMBIA, Md. (February 29, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $400,000 investment into Linshom Medical, Inc., a medical device company developing an innovative wearable sensor technology to support patient respiratory monitoring. This recent investment came in two parts – $250,000 from the State Small Business Credit Initiative (SSBCI) funding and $150,000 from the Venture Funds – and was done in conjunction with Abell Foundation.

TEDCO’s SSBCI funds were provided after the State of Maryland chose TEDCO to be one of the various stewards of this essential funding, allowing for more investments in target communities and areas with small, micro and Socially and Economically Disadvantaged Individual (SEDI) businesses. Click here to learn more.

gain therapeutics logo

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.

Based on the safety and tolerability profile observed in the Single Ascending Dose (SAD) cohorts of the study, the Bellberry Human Research Ethics Committee (HREC) in Australia approved the start of the MAD part of the study in parallel with the completion of the last SAD cohorts. Following the HREC approval, administration of GT-02287 in the MAD part of the study has been initiated.


MANASSAS, Va. & TEL AVIV, Israel--(BUSINESS WIRE)--ATCC, the world’s premier biological materials management and standards organization, and Tissue Dynamics, a disruptive pharma-tech company integrating advanced artificial intelligence tools with bionic human organoids, today announced a partnership to develop workflow friendly cardiac organoids-based kits for improved cardiac safety testing in drug development. The collaboration will be done under the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) framework, which awarded both companies a two-year grant. The BIRD Foundation, established in 1977, bolsters transformative partnerships that stimulate, promote, and support industrial research and development in a wide range of technology sectors.


When the Biden Administration unleashed its proposed march-in guidelines last December, it claimed they would be a powerful tool for lowering drug prices by allowing the government to “march in” to license copiers under the authorities of the Bayh-Dole Act.

It did so despite previously joining every other Administration denying price control petitions as not authorized under the law. It should have known the proposal would have minimal impact on drug prices—but would have a devastating impact on American innovation. That’s because the guidelines apply to all federal R&D agencies—not just the National Institutes of Health — so they cover inventions across the spectrum, not just the life sciences.

Lance Kawaguchi and Rich 250x600

Join us for an engaging episode of BioTalk as we sit down with Lance Kawaguchi, Chief Executive Officer of the Cure Brain Cancer Foundation. Lance's career trajectory from global finance to non-profit leadership is as inspiring as it is impactful, driven by a personal mission to combat brain cancer following the loss of his mother.

Listen now via your favorite podcast platforms:
Amazon Music:

In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for brain and rare cancer charities, culminating in a historic journey to the South Pole. We recognize Lance's leadership achievements, including ringing the Nasdaq bell twice as a cancer charity CEO, and his success in bringing the GBM AGILE Clinical Trial Platform from the US to Australia, accelerating breakthrough research efforts.

Click here to read the transcript.

Sci and tech park

Attention life sciences companies seeking lab space in Baltimore: Starting June 1st, a fully built-out lab/office space will be available at the Science & Technology Park at Johns Hopkins, located at 1812 Ashland Avenue. This 170,000 square foot facility is designed to accommodate companies at any stage, from startups to established firms.

The building hosts the Johns Hopkins "Fast Forward" innovation hub, promoting the advancement and commercialization of innovations. Situated within a community focused on research and development, it offers an unparalleled opportunity for companies to grow and collaborate in a leading-edge environment.

Don't miss this chance to locate your company in a premier life sciences hub. Contact Matthew L. Seward with Cushman & Wakefield for more details.

Click here to learn more.


Beyond the Breakthrough 112 Tatiana Litvin Vechnyak

Being a university in Washington DC poses interesting challenges, but Georgetown University's Tatiana Litvin-Vechnyak is determined to turn them into opportunities.

Weirdly, being located at the heart of the US capital doesn’t always help Georgetown University when it comes to creating spinout companies. State universities often have economic development mandates that they can follow, but in Washington DC Georgetown is in something of a vacuum — with little direction for what to focus on, less set funding and fewer people pushing to advance the technologies coming out of the institution.


AstraZeneca today announced the successful completion of the acquisition of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering AstraZeneca’s cell therapy ambition.

The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy. GC012F is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).

2023 Economic Impact Infographic 1

COLUMBIA, Md. (February 21, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced the findings of an independent economic impact study detailing the contributions of TEDCO’s six core programs to the state of Maryland. 

Conducted by the University of Baltimore’s Jacob France Institute, the study found that TEDCO continues to be a significant economic driving force in Maryland creating nearly $2.7 billion in statewide economic activity as of 2023.  TEDCO has invested in or supported the growth of a portfolio of 442 of Maryland’s leading technology companies, more than doubling the number of companies identified in the first TEDCO impact study in 2008.


First Lady Jill Biden announces funding as first major deliverable from new White House Initiative on Women’s Health Research 

As the first major deliverable of the White House Initiative on Women’s Health Research, the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS), today announced the ARPA-H Sprint for Women’s Health, which commits $100 million towards transformative research and development in women’s health. ARPA-H, which was created in 2022 as part of President Biden’s bipartisan Unity Agenda, seeks to advance and accelerate health solutions. 


GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

"Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent,” said Zsolt Harsanyi, Ph.D., chairman of the Board of Directors. “He is a recognized industry leader with unparalleled experience in all facets of the pharmaceutical and healthcare industry. Joe has a solid track record of driving growth and successfully navigating companies through periods of transformation. His leadership will be instrumental in strengthening Emergent’s balance sheet and returning to growth, as we continue to deliver on our mission to protect and enhance life. On behalf of the Board, I would also like to thank Haywood Miller for his leadership and contributions during this interim period.”


Washington DC: The heart of the BioHealth Capital Region

The BioHealth Capital Region (BHCR) encompasses Maryland, Virginia, and Washington D.C., and more than 1,800 life science and companies are established there. BHCR is among the top-performing biotech clusters in the U.S., with first-class educational facilities, innovative companies, and over 70 federal labs. While the area of Washington D.C. is smaller than Virginia and Maryland where companies are spread across, Washington is still a destination of choice with innovative biotech companies and events

The BHCR was ranked third biopharma cluster in the U.S. by Genetic Engineering and Biotechnology News behind the San Francisco Bay Area and the Boston/Cambridge area. The criteria to measure the performance of these hubs were the National Institutes of Health funding, venture capital funding, the number of biotechnology patents, the total lab space, and the number of jobs. This region, with Washington D.C. at its heart, is one of the most dynamic in the biotech industry.


rileybrown michelle

By Sara Gilgore – Staff Reporter, Washington Business Journal - 

It was her mother’s 86th birthday when Michelle Riley-Brown received a call that would change the trajectory of her career.

Holding the phone to her ear in her Houston home on March 3, 2023, the veteran health executive learned she was not only the first woman — but the first African American woman — to be named president and CEO of Children’s National Hospital in D.C.

The New Orleans native and youngest of five siblings — four of whom went into health care — immediately thought of her late father, a general surgeon who dedicated his life to medicine.

GSK Logo

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

As previously announced,1 the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma).2 AIO-001 has the potential to be administered every six months due to its high potency and long half-life, which could redefine the standard-of-care.


The National Institutes of Health is investing $515 million more into long COVID research efforts, three years after launching the initiative with $1.15 billion.

The cash infusion for the Recover program, announced Tuesday, will bolster ongoing research into the underlying biology and potential treatments for long COVID. NIH Director Monica Bertagnolli, M.D., said in a release that nearly 90,000 people were participating in ongoing Recover observational trials across more than 300 sites. 

“The amount of data being produced is unparalleled compared to any program in the world,” Bertagnolli said.